LFG
CRNX

Larson Financial Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Larson Financial Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4K Hold
64
– – ﹤0.01% 3057
2026
Q1 		$2.32K Sell
64
-227
-78% -$10.1K ﹤0.01% 2912
2025
Q4 		$13.5K Buy
291
+227
+355% +$10.1K ﹤0.01% 1947
2025
Q3 		$2.67K Buy
64
+20
+45% +$639 ﹤0.01% 2592
2025
Q2 		$1.26K Buy
+44
New +$1.36K ﹤0.01% 2566

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's CRNX Position: Q2 2026 in Review

Larson Financial Group held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 64 shares worth $2.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3057.

Larson Financial Group first reported a position in CRNX in Q2 2025 and has held it in 5 quarters since. The position peaked at $13.5K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Larson Financial Group held 64 shares of Crinetics Pharmaceuticals worth $2.4K as of Q2 2026.
  • Larson Financial Group left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3057 holding.
  • Larson Financial Group first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Larson Financial Group's Crinetics Pharmaceuticals position peaked at $13.5K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.